Skip to content
sellWeak cluster of 310b5-1 plan

Martine A Rothblatt sold $4.8M of UTHR

Chairperson & CEO at UNITED THERAPEUTICS Corp. 9,500 shares at an average of $504.12, traded Sep 14, 2026, filed Sep 15, 2026.

Warning score
30
Value
$4.8M
9,500 shares
Holdings after
324,443
-3% from before
From 52-week low
+26%
low $397.97, close $502.70
From 52-week high
-16%
high $596.76, as of Sep 14, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $4.8M at market
    +25
  • Share of holdings sold
    Sold 2.8% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

UTHROct 9, 2026 · close 549.16
Since filing Sep 15, 2026: +9.8%SPY +3.1% · excess +6.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001106578-26-000141, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 14, 2026MOption exercise
Common Stockindirect: by Trust10b5-1
+9,500$117.76$1.1M333,94327 d ago
Sep 14, 2026SOpen-market sale
Common Stockindirect: by Trust10b5-1
-1,580$502.15$793k332,36327 d ago
Sep 14, 2026SOpen-market sale
Common Stockindirect: by Trust10b5-1
-2,358$503.44$1.2M330,00527 d ago
Sep 14, 2026SOpen-market sale
Common Stockindirect: by Trust10b5-1
-2,722$504.47$1.4M327,28327 d ago
Sep 14, 2026SOpen-market sale
Common Stockindirect: by Trust10b5-1
-2,400$505.25$1.2M324,88327 d ago
Sep 14, 2026SOpen-market sale
Common Stockindirect: by Trust10b5-1
-440$506.48$223k324,44327 d ago
Sep 14, 2026MOption exercise
Stock Optionderivativeindirect: by Trust10b5-1
-9,500$0.00$0442,41027 d ago

Related signals

Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$5.1M
9,500 shares
-3%
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$5.2M
9,500 shares
-3%
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$5.1M
9,500 shares
-3%
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$5.1M
9,500 shares
-3%
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$5.2M
9,500 shares
-3%
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$5.5M
9,500 shares
-3%
18Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Paul A Mahon
EVP & GENERAL COUNSEL
$4.7M
8,300 shares
-16%
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$3.9M
7,580 shares
-2%
38Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$1.1M
1,920 shares
-1%
23Weak
UTHRsell 210b5-1
UNITED THERAPEUTICS Corp
Martine A Rothblatt
Chairperson & CEO
$4.5M
9,500 shares
-3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Martine A Rothblatt sold $4.8M of UTHR | InsiderTell